185 related articles for article (PubMed ID: 27038710)
1. Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative/nitrosative stress and inflammation.
Toblli JE; Cao G; Rivas C; Giani JF; Dominici FP
Int J Cardiol; 2016 Jun; 212():84-91. PubMed ID: 27038710
[TBL] [Abstract][Full Text] [Related]
2. Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Des Devel Ther; 2017; 11():2251-2263. PubMed ID: 28814833
[TBL] [Abstract][Full Text] [Related]
3. Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.
Jing W; Nunes ACF; Farzaneh T; Khazaeli M; Lau WL; Vaziri ND
J Pharmacol Exp Ther; 2018 Oct; 367(1):129-137. PubMed ID: 30093458
[TBL] [Abstract][Full Text] [Related]
4. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Inflamm Allergy Drug Targets; 2012 Feb; 11(1):66-78. PubMed ID: 22309085
[TBL] [Abstract][Full Text] [Related]
5. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator.
Toblli JE; Cao G; Angerosa M
Biometals; 2015 Apr; 28(2):279-92. PubMed ID: 25609135
[TBL] [Abstract][Full Text] [Related]
6. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
8. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
[TBL] [Abstract][Full Text] [Related]
9. Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron.
Toblli JE; Di Gennaro F; Rivas C
Heart Lung Circ; 2015 Jul; 24(7):686-95. PubMed ID: 25666998
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
[TBL] [Abstract][Full Text] [Related]
11. Coenzyme Q10 prevents oxidative stress and fibrosis in isoprenaline induced cardiac remodeling in aged rats.
Ulla A; Mohamed MK; Sikder B; Rahman AT; Sumi FA; Hossain M; Reza HM; Rahman GMS; Alam MA
BMC Pharmacol Toxicol; 2017 Apr; 18(1):29. PubMed ID: 28427467
[TBL] [Abstract][Full Text] [Related]
12. Oxidative effect of several intravenous iron complexes in the rat.
Bailie GR; Schuler C; Leggett RE; Li H; Li HD; Patadia H; Levin R
Biometals; 2013 Jun; 26(3):473-8. PubMed ID: 23681275
[TBL] [Abstract][Full Text] [Related]
13. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(10):553-65. PubMed ID: 22164963
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
Conner TA; McQuade C; Olp J; Pai AB
Biometals; 2012 Oct; 25(5):961-9. PubMed ID: 22706571
[TBL] [Abstract][Full Text] [Related]
16. Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair.
Tsuneyoshi H; Nishina T; Nomoto T; Kanemitsu H; Kawakami R; Unimonh O; Nishimura K; Komeda M
Circulation; 2004 Sep; 110(11 Suppl 1):II174-9. PubMed ID: 15364859
[TBL] [Abstract][Full Text] [Related]
17. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
[TBL] [Abstract][Full Text] [Related]
18. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia.
Beck-da-Silva L; Piardi D; Soder S; Rohde LE; Pereira-Barretto AC; de Albuquerque D; Bocchi E; Vilas-Boas F; Moura LZ; Montera MW; Rassi S; Clausell N
Int J Cardiol; 2013 Oct; 168(4):3439-42. PubMed ID: 23680589
[TBL] [Abstract][Full Text] [Related]
19. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
20. Qiliqiangxin improves cardiac function and attenuates cardiac remodeling in rats with experimental myocardial infarction.
Wang J; Zhou J; Ding X; Zhu L; Jiang K; Fu M; Wang S; Hu K; Ge J
Int J Clin Exp Pathol; 2015; 8(6):6596-606. PubMed ID: 26261541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
